Immatics N.V. (IMTX)
The price, the headline numbers and the latest news, in one place.
Immatics N.V. (IMTX) Stock Price, Analysis & Data
| Bid | 9.35 |
| Market Cap | 1.44B |
| Revenue (ttm) | 41.7M |
| Net Income (ttm) | -206.55M |
| 1.32 | |
| -1.86 | |
| n/a | |
| -4.57 | |
| P/B (ttm) | 2.77 |
| P/S (ttm) | 34.49 |
| Earnings Date | Nov 17, 2026 |
| Ask | 12.1 |
| Volume | 1,093,516 |
| Avg. Volume (20D) | 485,479 |
| Open | 9.68 |
| Previous Close | 9.36 |
| Day's Range | 9.32 - 9.88 |
| 52-Week Range | 5.05 - 12.41 |
| Analyst | Strong Buy |
| Price Target | 17 (79.89%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About IMTX
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203)...
Financial Performance
In 2025, Immatics's revenue was 48.27M, a decrease of -69.03% compared to the previous year's 155.84M. Earnings were -196.45M, a decrease of -1,390.89%.
Financial StatementsAnalyst Forecast
According to 6 analyst ratings, the average rating for IMTX stock is "Strong Buy". The 12-month stock price forecast is 17, which is upside of 79.89% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $7.61M misses estimates by $0, with -59.04% YoY decline.
- EPS of -0.53 misses estimates by -0.05, with 22.06% YoY growth.
Analysts project revenue of ... Upgrade
